THERAPY DOSSIER · th-e935af7b91ae

Vanillyl nonanoate

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL75124 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Nonivamide; N-vanillylnonamide; Nonylic acid vanillylamide; Pseudocapsaicin; AH-23491X
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02300311 ↗PHASE3completed

Finalgon Cream (Nicoboxil/Nonivamide) in Acute Low Back Pain

Low Back Pain

Enrolment: 138 · Results not recorded

NCT01708915 ↗PHASE3completed

Nicoboxil/Nonivamide Ointment vs Components and Placebo in Acute Low Back Pain

Acute Low Back Pain

Enrolment: 805 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21640099 ↗2011Reported benefit

Vanillyl nonanoate protects rat gastric mucosa from ethanol-induced injury through a mechanism involving calcitonin gene-related peptide.

RatChemical/toxinSprague-DawleyMale1 mg/kgPretreatment (before ethanol)

Model: Acidified ethanol-induced gastric mucosal injury

Vanillyl nonanoate protected against ethanol-induced gastric mucosal injury in rats by stimulating CGRP release and reducing inflammation, apoptosis and oxidative stress.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…